🎉 M&A multiples are live!
Check it out!

MannKind Valuation Multiples

Discover revenue and EBITDA valuation multiples for MannKind and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

MannKind Overview

About MannKind

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.


Founded

1991

HQ

United States of America
Employees

407

Financials

LTM Revenue $295M

LTM EBITDA n/a

EV

$1.3B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

MannKind Financials

MannKind has a last 12-month revenue of $295M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, MannKind achieved revenue of $286M and an EBITDA of $77.5M.

MannKind expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See MannKind valuation multiples based on analyst estimates

MannKind P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $199M $286M XXX XXX XXX
Gross Profit $42.3M $136M XXX XXX XXX
Gross Margin 21% 48% XXX XXX XXX
EBITDA $20.6M $77.5M XXX XXX XXX
EBITDA Margin 10% 27% XXX XXX XXX
Net Profit -$87.4M -$11.9M XXX XXX XXX
Net Margin -44% -4% XXX XXX XXX
Net Debt $204M $30.2M XXX XXX XXX

Financial data powered by Morningstar, Inc.

MannKind Stock Performance

As of April 15, 2025, MannKind's stock price is $5.

MannKind has current market cap of $1.4B, and EV of $1.3B.

See MannKind trading valuation data

MannKind Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.3B $1.4B XXX XXX XXX XXX $0.12

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

MannKind Valuation Multiples

As of April 15, 2025, MannKind has market cap of $1.4B and EV of $1.3B.

MannKind's trades at 4.3x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate MannKind's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for MannKind and 10K+ public comps

MannKind Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.3B XXX XXX XXX
EV/Revenue 4.4x XXX XXX XXX
EV/EBITDA 16.2x XXX XXX XXX
P/E 51.0x XXX XXX XXX
P/E/Growth 0.7x XXX XXX XXX
EV/FCF 38.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get MannKind Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

MannKind Valuation Multiples

MannKind's NTM/LTM revenue growth is 12%

MannKind's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $0.3M for the same period.

Over next 12 months, MannKind's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate MannKind's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for MannKind and other 10K+ public comps

MannKind Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 43% XXX XXX XXX XXX
EBITDA Margin 27% XXX XXX XXX XXX
EBITDA Growth 276% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 39% XXX XXX XXX XXX
Revenue per Employee $0.7M XXX XXX XXX XXX
Opex per Employee $0.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 16% XXX XXX XXX XXX
Opex to Revenue 49% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

MannKind Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Drug Delivery Systems comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

MannKind M&A and Investment Activity

MannKind acquired  XXX companies to date.

Last acquisition by MannKind was  XXXXXXXX, XXXXX XXXXX XXXXXX . MannKind acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by MannKind

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About MannKind

When was MannKind founded? MannKind was founded in 1991.
Where is MannKind headquartered? MannKind is headquartered in United States of America.
How many employees does MannKind have? As of today, MannKind has 407 employees.
Who is the CEO of MannKind? MannKind's CEO is Mr. Michael E. Castagna, Pharm.D..
Is MannKind publicy listed? Yes, MannKind is a public company listed on NAS.
What is the stock symbol of MannKind? MannKind trades under MNKD ticker.
When did MannKind go public? MannKind went public in 2004.
Who are competitors of MannKind? Similar companies to MannKind include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of MannKind? MannKind's current market cap is $1.4B
What is the current revenue of MannKind? MannKind's last 12-month revenue is $295M.
What is the current EV/Revenue multiple of MannKind? Current revenue multiple of MannKind is 4.3x.
What is the current revenue growth of MannKind? MannKind revenue growth between 2023 and 2024 was 43%.
Is MannKind profitable? Yes, MannKind is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.